What to Expect During the First Few Weeks The starting dose is meant to prepare your body, not create dramatic changes overnight
0.6% of wild.type activtiy Y165H mutation identified in a in patient with classic galactosemia E203K - native heterozygous mutant, reduced activity by about 50% in erythrocytes E291K - site-directed mutagenesis for construction of the naturally occuring mutation, 62.8% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose E340X/L218L/N314D - native mutant, no or nearly no enzyme activity, L218L is a silent mutation, galactosemia phenotype F171L - site-directed mutagenesis, 10fold decreased activity F171W - site-directed mutagenesis, severely reduced abundance F171Y - site-directed mutagenesis, 4% activity compared to wild-type, no inhibition by excess UDP-glucose K285N - site-directed mutagenesis for construction of the naturally occuring mutation, below 0.2% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose L139P - site-directed mutagenesis for construction of the naturally occuring mutation, 1.9% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose L218L/N314D - native Duarte-1 D1 variant, L218L is a silent mutation, N314D leads to 110-130% activity compared to the wild-type N314D/E203K - homozygous N314D mutant with introduced cis mutation E203K does no longer show the reduced, but the full activity and increased thermolablity of mutant without E203K P183T - site-directed mutagenesis for construction of the naturally occuring mutation, 45.2% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose P185A - site-directed mutagenesis, reduced activity and reduced expression level compared to wild-type P185C - site-directed mutagenesis, no remaining activity, same expression level compared to wild-type P185D - site-directed mutagenesis, no remaining activity, same expression level compared to wild-type P185E - site-directed mutagenesis, reduced activity, same expression level compared to wild-type P185F - site-directed mutagenesis, no remaining activity, highly reduced expression level compared to wild-type P185G - site-directed mutagenesis, reduced activity and expression level compared to wild-type P185H - site-directed mutagenesis, no remaining activity, reduced expression level compared to wild-type P185I - site-directed mutagenesis, no remaining activity, highly reduced expression level compared to wild-type P185K - site-directed mutagenesis, no remaining activity, reduced expression level compared to wild-type P185L - site-directed mutagenesis, no remaining activity, highly reduced expression level compared to wild-type P185M - site-directed mutagenesis, no remaining activity, reduced expression level compared to wild-type P185N - site-directed mutagenesis, no remaining activity, reduced expression level compared to wild-type P185Q - site-directed mutagenesis, reduced activity, increased expression level compared to wild-type P185R - site-directed mutagenesis, no remaining activity, same expression level compared to wild-type P185S - site-directed mutagenesis, reduced activity, reduced expression level compared to wild-type P185T - site-directed mutagenesis, no remaining activity, reduced expression level compared to wild-type P185V - site-directed mutagenesis, no remaining activity, highly reduced expression level compared to wild-type P185W - site-directed mutagenesis, no remaining activity, highly reduced expression level compared to wild-type P185Y - site-directed mutagenesis, no remaining activity, reduced expression level compared to wild-type Q188N - site-directed mutagenesis, reduced activity R201H - site-directed mutagenesis for construction of the naturally occuring mutation, 62.8% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose R231H - site-directed mutagenesis for construction of the naturally occuring mutation, below 0.2% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose R258C - native mutant, 15-20% activity compared to wild-type, some clinical symptoms R259W - site-directed mutagenesis for construction of the naturally occuring mutation, below 0.2% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose R333G - native mutant, 20% activity compared to wild-type, no clinical symptoms R67C - site-directed mutagenesis for construction of the naturally occuring mutation, 2.3% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose T350A - site-directed mutagenesis for construction of the naturally occuring mutation, 9.9% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose V151A - site-directed mutagenesis for construction of the naturally occuring mutation, 4.6% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucosey W316X/N314D/G1105C/G1391A - native mutant, nearly no enzyme activity, galactosemia phenotype Y323D - site-directed mutagenesis for construction of the naturally occuring mutation, 9.6% of wild-type activity, accumulation of alpha-D-galactose 1-phosphate, UDP-galactose and UDP-glucose 44 - t1/2: 2 min, 2 mg/ml serum albumin stabilizes considerably 48 - t1/2: 1 min, 2 mg/ml serum albumin stabilizes considerably 50 - 15 min, 30% loss of activity for the wild-type enzyme, over 55% loss of activity for the homozygous N314D mutant additional information - increased thermal lability of the mutant N314D compared to the wild-type dithioerythritol stabilizes during purification - freeze-thawing inactivates purified enzyme - freezing of dilute enzyme solution inactivates, concentration procedures lead to considerable loss of activity - sulfhydryl reagents restore activity of partially denatured enzyme and protect against inactivation - UDP-glucose stabilizes during gel filtration - -20C, partially purified, 10% loss of activity per month - 0C, 10% loss of activity per week - 0C, purified enzyme, 10% loss of activity within 2 weeks - 0C, purified in the presence of dithioerythritol, 2 weeks - 4C, adsorbed to DEAE-cellulose, about 2 months - freezing inactivates purified enzyme - 70600fold from erythrocytes - His-tagged recombinant wild-type and mutants F171Y and F171L to near homogeneity - partial from erythrocyte, several isozymes - placental enzyme to homogeneity, coelutes with a 67 kDa glycoprotein - recombinant His-tagged wild-type and mutant S135L from yeast, to near homogeneity - recombinant His-tagged wild-type and mutants P185A, P185S, P185G, P185E, and P185Q to near homogeneity - recombinant His-tagged wild-type, partial 67fold, and mutants from Escherichia coli Bl21(DE3) - tagged mutant heterodimers from yeast - expression in Sacchaormyces cerevisiae cloning in Escherichia coli and coexpression in yeast of mutant heterodimers derived from galactosemic patients, use of different tags - expression as fusion protein with glutathione-S-transferase from Schistosoma japonicum in a bacterial expression system - expression of His- and 12CA5 epitope-tagged subunits of mutants R333W and Q188R in yeast, analysis of homo- and heterodimer formation of wild-type and mutant subunits - expression of N314D mutants in human lymphoblasts - expression of wild-type and mutants as His-tagged proteins in Escherichia coli Bl21(DE3) - expression of wild-type and mutants in Saccharomyces cerevisiae - expression of wild-type and mutants in yeast - overexpression of wild-type and mutant S135L as His-tagged proteins, 2fold lower expression than the wild-type, in a null-background yeast - the GALT gene is located on chromosome 9p13 - diagnostics - the enzyme activity is measured for determination of galactosaemia using erythrocyte from blood samples, HPLC-based method development, overview drug development - the enzyme might be a target for inhibitor design in galactosemia treatment Mayes, J.S
Often, nodules improve with voice therapy and behavior modifications alone
Studied for anti-inflammatory effects in gastrointestinal research models, with NF-kB pathway modulation as the principal proposed mechanism
Subcellular proteomics revealed the epithelial-mesenchymal transition phenotype in lung cancer
